ArticleBulletin of experimental biology and medicine2022
Clinical Significance of PAC-1, CD62P, and Platelet-Leukocyte Aggregates in Acute Ischemic Stroke.
Article in Bulletin of experimental biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods.Nature communications · 2026Pooled it
- CD71BMC nephrology · 2026Article
- Differential expression of serum TM, PAF, and CD62P in patients with autologous arteriovenous fistula and the correlation with vascular access function.Immunity, inflammation and disease · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied diagnostic and treatment values of the blood levels of platelet activation markers PNA, PMA, PLyA, PAC-1, and CD62P in 30 patients with acute ischemic stroke (median NIHSS score 4 (2; 6)) before and after treatment as well as in comparison with the control group. The levels of these markers were measured by flow cytometry. In patients with acute ischemic stroke, the levels of PLyA, PAC-1, and CD62P were significantly increased in comparison with the controls; therapy significantly reduced the levels of PAC-1, CD62P, and PMA in patients with acute ischemic stroke. The areas under the ROC curve differentiating acute ischemic stroke from healthy controls for PAC-1, CD62P, and PLyA were 0.694, 0.862, and 0.760, respectively. Our findings suggest that the levels of PLyA, PAC-1, and CD62P can be potential noninvasive biomarkers of acute ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.